Handok strengthens tie-ups with Nycomed

Published: 2010-04-02 06:56:00

Updated: 2010-04-02 06:56:00

Handok Pharm says its has signed an licensing agreement with Nycomed International Management GmbH, a global pharmaceutical company headquartered in Zurich, Switzerland for the exclusive distribution rights in Korea of Roflumilast, a new phosphodiesterase 4 inhibitor for chronic obstructive pulmonary disease.

Roflumilast has anti-inflammatory effects and is under development as an orally adm...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.